STRYKER (SYK) Company Report

Adjusted EPS of $4.47 and revenue of $7.17 billion topped expectations; GAAP profit was $849 million ($2.20 per share), reflecting an 11% year-over-year revenue gain.
Organic sales rose about 11%, driven by MedSurg & neurotechnology (up ~17.5%); segment revenues were $4.6 billion for MedSurg & neuro and $2.6 billion for orthopaedics.
Adjusted operating margin expanded by roughly 100 basis points to 30.2%, supporting full-year 2025 sales of $25.1 billion.
For 2026, management guides 8.0–9.5% organic net sales growth and $14.90–15.10 in adjusted EPS, above Wall Street forecasts.

5 days ago

Morningstar

Stryker announces Q4 2025 results

SYK

Earnings

Guidance Update

Revenue Acceleration/Inflection

11% organic sales growth in Q4 and 10.3% for the full year, driving total sales past $25 billion in 2025
Q4 adjusted EPS of $4.47 (up 11.5%) and full-year adjusted EPS of $13.63 (up 11.8%)
Strong Q4 segment performances: MedSurg & Neuro +12.6%, Instruments +19.1%, Endoscopy +11.1%, Medical +13.6%; Vascular +4.3%
Operating cash flow of $5 billion and free cash flow at 81% of adjusted net earnings, above 2024’s 75%
2026 guidance: 8%–9.5% organic net sales growth, adjusted EPS of $14.90–$15.10, and approximately $400 million in tariff impacts

5 days ago

Transcript

Stryker reports Q4 2025 results

SYK

Earnings

Guidance Update

Stryker delivered 11% organic sales growth in Q4 2025, up from 10.2% a year ago, and 10.3% full-year organic growth, supported by favorable pricing (+0.4%) and FX (+0.5%) impacts.
Q4 adjusted EPS was $4.47, up 11.5% y/y; full-year adjusted EPS reached $13.63, a 11.8% increase.
Q4 segment performance was highlighted by MedSurg & Neurotechnology organic growth of 12.6% (US +13%), Instruments US growth of 19.1%, and Endoscopy US growth of 11.1%.
Year-to-date cash from operations totaled $5.0 billion, driving free cash flow at 81% of adjusted net earnings versus 75% in 2024.
2026 guidance calls for 8–9.5% organic net sales growth, adjusted EPS of $14.90–$15.10, and a tariff headwind of approximately $400 million.

5 days ago

Transcript

Stryker reports Q4 and full-year 2025 results

SYK

Earnings

Guidance Update

Management Change

Stryker delivered 11% organic sales growth in Q4 and 10.3% for full-year 2025, surpassing $25 billion in sales, with 11.2% U.S. growth and 7.5% international growth.
The company achieved a record quarter of Mako 4 installations, exceeding 3,000 systems worldwide, with over two-thirds of U.S. knee and one-third of hip procedures performed on Mako.
For 2026, Stryker expects 8–9.5% organic sales growth, modest positive pricing, a slight FX benefit, and approximately $400 million in tariff headwinds (including $200 million in H1).
Spencer Stiles was promoted to President and Chief Operating Officer in December to lead global commercial operations and enable executive succession.

5 days ago

Transcript

Stryker reports Q4 2025 results and 2026 outlook

SYK

Earnings

Guidance Update

Fourth quarter net sales increased 11.4% to $7.2 billion, with organic growth of 11.0%; reported EPS of $2.20 (+56.0%) and adjusted EPS of $4.47 (+11.5%); adjusted operating margin expanded 100 bps to 30.2%.
Full year net sales grew 11.2% to $25.1 billion, organic growth of 10.3%; reported EPS of $8.40 (+8.2%) and adjusted EPS of $13.63 (+11.8%); adjusted operating margin up 100 bps to 26.3%.
Net cash from operating activities was $5.0 billion in FY 2025, while acquisitions (net of cash acquired) totaled $5.0 billion.
2026 guidance includes 8.0%–9.5% organic net sales growth and adjusted EPS of $14.90–$15.10, with a modestly positive impact from pricing and foreign exchange.

5 days ago

8-K

Forma Medical announces strategic focus on OptimalMTP, secures patent and appoints board member

SYK

Board Change

Forma Medical is prioritizing its strategic focus on OptimalMTP™, which has treated over 650 patients, to accelerate surgeon adoption and deepen clinical evidence.
The company secured U.S. Patent No. 12,521,157 covering minimally invasive joint fixation methods with low-profile plating constructs.
Aaron Smith, former CEO of Artelon (acquired by Stryker), was appointed to the Board of Directors to leverage his two decades of orthopedic leadership.
Forma Medical will present its advances at the ACFAS Annual Scientific Conference in Las Vegas from February 23–27, 2026.

6 days ago

Press Release

Stryker outlines growth strategy at Investor Day 2025

SYK

M&A

Guidance Update

Product Launch

Continued fast growth driven by prioritized M&A in high-growth areas (e.g., healthcare IT with Vocera, Care.ai and Inari) to raise the weighted average market growth rate
Decentralized operating model with specialized business units (GM-led sales, marketing, R&D) complemented by Customer Solutions for pricing, contracting and ASC programs to deliver comprehensive offerings
Financial commitment to double-digit EPS growth in 2026–2028, with ~70% of capital allocated to acquisitions, moderate dividend increases and no share buybacks planned
Emphasis on innovation across power brands—including robotics, 3D-printed implants, the virtual nurse (Care.ai) and the newly FDA-cleared MAKO RPS handheld robotic system for joint replacement’s standard-of-care segment

Nov 13, 2025, 7:30 PM

Transcript

Stryker Reports 10% Q3 Sales Growth, Raises 2025 Guidance

SYK

Earnings

Guidance Update

Product Launch

Third-quarter net sales rose 10.3% to $6.1 billion, and adjusted EPS increased 11.1% to $3.19, outperforming expectations.
Full-year outlook raised to 9.8%–10.2% organic net sales growth and $13.50–$13.60 adjusted EPS.
Operating income margin was 18.7% (adjusted 25.6%), while free cash flow margin declined to 22.3% from 23.7%, indicating some margin pressure.
Innovation pipeline advanced with the FDA-cleared Incompass total ankle system launch and a neurovascular robotics partnership with Siemens Healthineers.

Oct 31, 2025, 6:04 AM

WSJ

Stryker reports Q3 2025 results

SYK

Earnings

Guidance Update

M&A

Delivered 9.5% organic sales growth and $3.19 adjusted EPS (+11.1% y/y) in Q3 2025
Raised full-year 2025 guidance to 9.8%–10.2% organic sales growth and $13.50–$13.60 EPS
Achieved 65% adjusted gross margin (+50 bps) and 25.6% adjusted operating margin (+90 bps) despite ~$200 million tariff impact
Completed tuck-in acquisitions of Guard Medical NP Seal and Advanced Medical Balloons and advanced Inari integration with $590 million pro forma sales in 10 months

Oct 30, 2025, 8:30 PM

Transcript

Stryker reports Q3 2025 results and raises full-year outlook

SYK

Earnings

Guidance Update

M&A

Organic sales grew 9.5% year-over-year and adjusted EPS was $3.19, up 11.1%, driven by strong demand across businesses.
Adjusted gross margin reached 65% (up 50 bp) and adjusted operating margin was 25.6% (up 90 bp); year-to-date operating cash flow was $2.9 billion.
MedSurg & Neurotechnology sales rose 8.4% (U.S. +9.4%, International +5.1%) and Orthopaedics grew 11.4% (U.S. +12.9%, International +7.8%).
Completed small tuck-in acquisitions of Guard Medical’s NP Seal and Advanced Medical Balloons and emphasized continued M&A activity.
Raised full-year 2025 guidance to 9.8%–10.2% organic net sales growth and $13.50–$13.60 adjusted EPS.

Oct 30, 2025, 8:30 PM

Transcript

Earnings Transcripts

Quarterly earnings call transcripts for STRYKER.

Q4 2025

Jan 29, 2026

→

Q3 2025

Oct 30, 2025

→

Q2 2025

Jul 31, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Kevin Lobo say about margins?What are STRYKER's strategic priorities?How is STRYKER positioned vs competitors?How did STRYKER do last quarter?

STRYKER (SYK)

Analyst Earnings Quarterly Reports

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Q4 2025

Executives

Kevin Lobo

Andrew Pierce

Preston Wells

Spencer Stiles

Viju Menon

Board Members

Andrew Silvernail

Emmanuel Maceda

Giovanni Caforio

Lisa Skeete Tatum

Mary Brainerd

Rachel Ruggeri

Rajeev Suri

Ronda Stryker

Sherilyn McCoy

Analyst Coverage

Danielle Antalffy

Travis Steed

Vijay Kumar

Joanne Wuensch

Ryan Zimmerman

Richard Newitter

David Roman

Larry Biegelsen

Matthew O'Brien

Matt Miksic

Michael Matson

Robert Marcus

Shagun Singh Chadha

Chris Pasquale

Caitlin Cronin

Jenny Rabinowitz

Matthew Miksic

Mike Matson

Patrick Wood

Pito Chickering

Robbie Marcus

Caitlin Roberts

Drew Ranieri

Eric Anderson

Jeff Johnson

Kendall

Larry Beagleson

Matthew Taylor

Philip Chickering

Samantha Kurtz

Steven Lichtman

Christopher Pasquale

Jason Wittes

Jeffrey Johnson

Joshua Jennings

Kaitlin Cronin

Lawrence Biegelsen

Matthew Aspro

Matt O'Brien

Michael Polark

Latest news

Earnings Transcripts

Q4 2025

Q3 2025

Q2 2025

Ask Fintool AI Agent